The University of California, San Diego (UCSD) has been awarded a $592,500 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The objective of this 3-year grant, with a period of performance from February 1, 2025 to January 31, 2028, is to develop a "Mutant DNA-Activated Killing System for Precision Breast Cancer Therapy." This innovative research project aims to advance the treatment of breast cancer through the use of novel therapeutic approaches involving genetically engineered systems. UCSD, a leading academic research institution, will leverage its expertise in areas such as molecular biology, oncology, and biomedical engineering to conduct this cutting-edge investigation. The findings from this grant-funded research have the potential to significantly improve medical outcomes for military service members and the broader population affected by breast cancer.
Generated 3/4/25, 7:26 AM